ED-Finanzas

No es posible guardar favoritos sin iniciar sesión.

Usá Login / Registrar en el header (usuario + contraseña).

OSRH

OSR Health Inc · NASD

Healthcare · Biotechnology · USA · Nano

0.59
+0.27 (+86.71%)
Aug 17 3:59 PM ET

OSR Health, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

Chart

Lightweight Charts · Yahoo Finance

Date Headline URL From
Aug-11-26 08:52AM OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development link (ACCESSWIRE)
Aug-07-26 03:00PM OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program link (ACCESSWIRE)
Aug-03-26 09:02AM Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform link (ACCESSWIRE)
Jul-31-26 12:00PM OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment link (ACCESSWIRE)
Jul-13-26 12:37PM OSR Health, A Message From the CEO link (ACCESSWIRE)
Jul-02-26 01:05PM CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target link (ACCESSWIRE)
Jul-02-26 09:00AM Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target link (ACCESSWIRE)
Jun-25-26 08:32AM OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares link (ACCESSWIRE)
Jun-22-26 09:06AM OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do link (ACCESSWIRE)
Jun-03-26 12:05PM CEO Statement to Shareholders link (ACCESSWIRE)
May-27-26 09:06AM OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction link (ACCESSWIRE)
May-12-26 09:16AM CEO Statement to Shareholders link (ACCESSWIRE)
May-05-26 01:05PM Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target link (ACCESSWIRE)
Apr-30-26 10:30AM BC-Most Active Stocks link (Associated Press)
Apr-30-26 09:15AM OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 link (ACCESSWIRE)
Apr-29-26 09:50AM OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe link (ACCESSWIRE)
Apr-09-26 09:15AM OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note link (ACCESSWIRE)
Mar-30-26 09:00AM OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 link (ACCESSWIRE)
Mar-27-26 09:00AM Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target link (ACCESSWIRE)
Mar-23-26 08:30AM OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level link (ACCESSWIRE)
Mar-19-26 09:44AM Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials link (PR Newswire)
Mar-19-26 08:55AM Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities link (ACCESSWIRE)
Mar-05-26 09:30AM OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum link (ACCESSWIRE)
Feb-02-26 09:50AM CEO Statement to Shareholders link (ACCESSWIRE)
Jan-27-26 08:30AM OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries link (ACCESSWIRE)
Jan-22-26 09:55AM Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch link (PR Newswire)
Jan-16-26 09:20AM Vaximm Appoints Sebastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform link (PR Newswire)
Jan-12-26 08:05AM Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones link (PR Newswire)
Dec-19-25 11:50AM Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings link (PR Newswire)
Dec-04-25 03:19PM Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement link (Newsfile)
Dec-02-25 09:53AM Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months link (PR Newswire)
Dec-01-25 03:01PM OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 link (PR Newswire)
Nov-21-25 09:20AM Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones link (PR Newswire)
Nov-14-25 11:10AM OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion link (PR Newswire)
Nov-06-25 08:30AM OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study link (PR Newswire)
Oct-20-25 11:40AM Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target link (Newsfile)
Oct-14-25 08:30AM OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care link (PR Newswire)
Sep-09-25 05:30PM OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity link (PR Newswire)
Aug-25-25 10:30AM BC-Most Active Stocks link (Associated Press Finance)
Aug-01-25 01:29PM OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025 link (PR Newswire)
Jul-31-25 12:45PM OSR Holdings Provides Transparency Update on Equity Financing Instruments link (PR Newswire)
Jul-30-25 04:10PM OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure link (PR Newswire)
Jul-28-25 05:49AM OSR Holdings to acquire South Koreas medical device company Woori IO link (Medical Device Network)
Jul-24-25 07:30AM OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology link (PR Newswire)
Jul-15-25 07:30AM OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company link (PR Newswire)
Jul-08-25 10:03AM OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG link (PR Newswire)
May-22-25 07:36AM OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token link (PR Newswire)
May-02-25 07:30AM Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics link (PR Newswire)
Apr-09-25 07:54AM Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology link (PR Newswire)
Apr-03-25 07:30AM OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies link (PR Newswire)
Mar-26-25 07:16AM Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma link (PR Newswire)
Mar-25-25 07:00AM OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer link (PR Newswire)